Radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin): the role of the nuclear medicine physician.
Semin Nucl Med. 2004 Jan;34(1):S2-3
Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Semin Nucl Med. 2004 Jan;34(1):S4-9
Imaging and dosing in radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Semin Nucl Med. 2004 Jan;34(1):S10-3
Logistics of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Semin Nucl Med. 2004 Jan;34(1):S14-9
Radiation safety considerations with yttrium 90 ibritumomab tiuxetan (Zevalin).
Semin Nucl Med. 2004 Jan;34(1):S20-3
Impact of functional genomics and proteomics on radionuclide imaging.
Semin Nucl Med. 2004 Jan;34(1):4-22
The Na/I symporter (NIS): imaging and therapeutic applications.
Semin Nucl Med. 2004 Jan;34(1):23-31
Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs.
Semin Nucl Med. 2004 Jan;34(1):32-46
Molecular imaging in nuclear cardiology.
Semin Nucl Med. 2004 Jan;34(1):47-55
Implications of PET based molecular imaging on the current and future practice of medicine.
Semin Nucl Med. 2004 Jan;34(1):56-69
Neurochemical imaging of dementias.
Semin Nucl Med. 2004 Jan;34(1):70-82